Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026
The study moves Humacyte’s coronary vessel into human testing after preclinical work in multiple large-animal models.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Humacyte (HUMA) has initiated a first-in-human Phase 2a study of its bioengineered coronary vessel for coronary artery bypass surgery. The study is open for enrollment and will evaluate safety and efficacy in ten adults with coronary artery disease. Vessel patency, or whether the graft remains open, will be assessed two months after implantation, with follow-up for up to three years. The FDA accepted the investigational new drug application in July 2026.
Presentations at the American Heart Association Scientific Sessions 2026 included preclinical results showing implanted vessels remained open for up to three months in sheep, with host cells populating the vessel walls. The coronary vessel remains investigational and is not approved for sale.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointFirst-in-human Phase 2a coronary bypass study initiated and open for enrollment.
- Minor pointFDA acceptance of the coronary vessel’s investigational new drug application occurred in July 2026.
- Minor pointSheep implants demonstrated patency and host-cell repopulation with ~12 cm-long bypasses for up to three months.
- Minor pointPrevious baboon study showed mechanical integrity and patency for up to six months, with host-cell repopulation.
Negative
- None.
Details
Market move: HUMA +8.08% vs previous close. Phase 2a clinical study
On Nov 9, the day this news came out, the latest delayed price for HUMA is 8.08% above the previous close. Our momentum scanner has recorded 19 alerts for this stock so far that day. The latest delayed price is $0.48.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Study enrollment
- 10 adult patients
- Phase 2a CTEV study in coronary artery bypass grafting
- Patency assessment
- 2 months after implant
- Phase 2a study
- Patient follow-up
- Up to 3 years
- Phase 2a study
- Sheep-model bypass length
- ~12 cm
- CTEV CABG bypasses
- Sheep-model patency
- Up to 3 months
- Successful implantation with patency and host recellularization
- Baboon-model patency
- Up to 6 months
- Prior preclinical CABG study
- Annual U.S. coronary arterial grafts
- More than 400,000 per year
- Background CABG volume
- Saphenous vein graft patency
- As low as 75% at one year
- Article's description of current CABG conduits
Historical Context
-
Announced presentations of the Phase 2a study design and preclinical CABG work
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cabg medical
investigational new drug regulatory
patency medical
endothelial cells medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Humacyte has initiated the CABG clinical study and looks forward to the commencement of screening for potential patients.
– “Moving it into a first-in-human study is the step that will tell us whether an off-the-shelf conduit can perform in the coronary position,” says cardiothoracic surgeon Alan Kypson, M.D.
DURHAM, N.C., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced that it has initiated the Phase 2a study of its investigational coronary tissue engineered vessel (CTEV) in patients undergoing coronary artery bypass grafting (CABG). The CTEV and the Company’s regenerative medicine platform were highlighted in three presentations at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois. The AHA Scientific Sessions is one of the world’s largest gatherings of cardiovascular clinicians and scientists.
On Saturday, November 7, John H. Alexander, M.D., M.H.S., Professor of Medicine/Cardiology, Duke Clinical Research Institute at Duke University and Alan Kypson, M.D., Cardiothoracic Surgeon at UNC Rex Hospital, presented the design of the Phase 2a study in “First-in-Human Phase 2a Study Design of a Bioengineered Human Coronary Artery for Coronary Artery Bypass Grafting.” The FDA accepted Humacyte’s Investigational New Drug (IND) application in July 2026, and the study will evaluate the safety and efficacy of the CTEV as a vascular conduit in ten adult patients with coronary artery disease. Patency will be assessed two months after implant, and patients will be followed for up to three years. The study is now open for enrollment.
“Every cardiac surgeon has faced the patient who needs a bypass, but doesn’t have usable vein, and our options in those cases are limited,” said Dr. Kypson. “I have worked with this vessel in large-animal models for years and moving it into a first-in-human study is the step that will tell us whether an off-the-shelf conduit can perform in the coronary position.”
More than 400,000 coronary arterial grafts are placed each year in the United States. The current conduits used for CABG are autologous vessels harvested from the patient, most often the saphenous vein in the leg. However, saphenous vein graft patency at one year is often as low as
On Saturday, November 7, Dr. Niklason delivered an invited talk, “Engineering the Microenvironment to Accelerate Vascular Regeneration,” in a special session on bioengineering human tissue for congenital heart disease, describing how Humacyte’s acellular engineered vessels are designed to be repopulated by a patient’s own cells after implantation, and may serve as materials to form biological heart valves that could grow with the pediatric patient.
“The Phase 2a CABG study marks the first time our bioengineered vessel technology will be evaluated in coronary bypass surgery, and it builds on years of preclinical work in multiple large-animal models,” said Dr. Niklason. “Our goal with the CTEV is to give cardiac surgeons an off-the-shelf conduit that can repopulate with a patient’s own cells, without the need to harvest a vein from the leg or an artery from the arm.”
On Sunday, November 8, Robert Kirkton, Ph.D., Executive Director of New Product and Process Development at Humacyte, presented results from porcine and ovine CABG models in “Evaluation of Tissue Engineered Human Vessels in Porcine and Ovine Models of Coronary Artery Bypass Grafting.” These results included successful implantation of ~12 cm-long CTEV bypasses for up to three months in sheep demonstrating patency and host recellularization of the CTEV wall with smooth muscle cells as well as luminal endothelial cells along the length of the CTEV CABG conduit. This work builds on a previous preclinical CABG study in baboons, published in JACC: Basic to Translational Science, in which the CTEV maintained mechanical integrity and conduit patency for up to six months while becoming recellularized with host vascular smooth muscle and endothelial cells.
The CTEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What will Humacyte’s first-in-human coronary bypass study evaluate?
The Phase 2a study will evaluate the safety and efficacy of Humacyte’s coronary tissue engineered vessel in ten adults with coronary artery disease. Graft patency will be assessed two months after implantation, and patients will be followed for up to three years. The study is open for enrollment.
What did the earlier baboon study show about Humacyte’s coronary vessel?
The earlier preclinical baboon study showed mechanical integrity and conduit patency for up to six months, while host vascular smooth muscle and endothelial cells repopulated the vessel. The work was published in JACC: Basic to Translational Science.